Initial experiences with the Hemopatch ® as a hemostatic agent in zero-ischemia partial nephrectomy
Conclusions
Although this study is limited to a small set of initial experiences with Hemopatch® in LPN, it proves the feasibility and reliability of this new hemostat. Following further evaluation in prospective randomized comparative studies, Hemopatch® might represent a promising tool in NSS.
Source: World Journal of Urology - Category: Urology & Nephrology Source Type: research
More News: Bleeding | Cancer & Oncology | Laparoscopy | Nephrectomy | Pathology | Polyethylene Glycol | Study | Urology & Nephrology